lapatinib has been researched along with Body Weight in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Balansky, R; Camoirano, A; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; Izzotti, A; La Maestra, S; Longobardi, M; Micale, RT; Steele, VE | 1 |
Cao, S; Gao, H; Jiang, X; Pang, Z; Xi, Z; Yang, Z; Zhang, S | 1 |
2 other study(ies) available for lapatinib and Body Weight
Article | Year |
---|---|
Assay of lapatinib in murine models of cigarette smoke carcinogenesis.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; DNA Adducts; DNA Damage; Erythrocytes; Gene Expression Regulation; Lapatinib; Lung; Lung Neoplasms; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2014 |
Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Coumarins; Endocytosis; Fluorescent Antibody Technique; Glioma; Humans; Imaging, Three-Dimensional; In Situ Nick-End Labeling; Lapatinib; Lipoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanoparticles; Osteonectin; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Xenograft Model Antitumor Assays | 2012 |